奥利司他对肥胖女性多囊卵巢综合征的影响

Qi Jiang, Yuhua Shi
{"title":"奥利司他对肥胖女性多囊卵巢综合征的影响","authors":"Qi Jiang, Yuhua Shi","doi":"10.1097/JBR.0000000000000017","DOIUrl":null,"url":null,"abstract":"Polycystic ovary syndrome (PCOS) is a common gynecological endocrine syndrome characterized by metabolic abnormality and reproductive dysfunction, including ovulation abnormality, hyperandrogenism and polycystic ovarian manifestations. Most PCOS patients are overweight or obese, particularly the central type. This aggravates the clinical manifestations of PCOS and ultimately increases the risk of infertility. Orlistat is the only weight loss drug approved by the US Food and Drug Administration. As a long-lasting gastrointestinal lipase inhibitor, orlistat can effectively reduce the absorption of lipid and increase lipid excretion, thereby achieving weight loss. In obese PCOS patients, orlistat can reduce weight, improve lipid metabolism and insulin resistance, improve sex hormone disorder, and have a positive effect on pregnancy outcome. This review summarizes the impact of orlistat treatment on metabolism and fertility in obese women with PCOS. \n \n \nKey words: \nhyperandrogenism; insulin resistance; obesity; orlistat; polycystic ovary syndrome; pregnancy outcome","PeriodicalId":150904,"journal":{"name":"Journal of Bio-X Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of orlistat on obese women with polycystic ovary syndrome\",\"authors\":\"Qi Jiang, Yuhua Shi\",\"doi\":\"10.1097/JBR.0000000000000017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Polycystic ovary syndrome (PCOS) is a common gynecological endocrine syndrome characterized by metabolic abnormality and reproductive dysfunction, including ovulation abnormality, hyperandrogenism and polycystic ovarian manifestations. Most PCOS patients are overweight or obese, particularly the central type. This aggravates the clinical manifestations of PCOS and ultimately increases the risk of infertility. Orlistat is the only weight loss drug approved by the US Food and Drug Administration. As a long-lasting gastrointestinal lipase inhibitor, orlistat can effectively reduce the absorption of lipid and increase lipid excretion, thereby achieving weight loss. In obese PCOS patients, orlistat can reduce weight, improve lipid metabolism and insulin resistance, improve sex hormone disorder, and have a positive effect on pregnancy outcome. This review summarizes the impact of orlistat treatment on metabolism and fertility in obese women with PCOS. \\n \\n \\nKey words: \\nhyperandrogenism; insulin resistance; obesity; orlistat; polycystic ovary syndrome; pregnancy outcome\",\"PeriodicalId\":150904,\"journal\":{\"name\":\"Journal of Bio-X Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bio-X Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/JBR.0000000000000017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bio-X Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/JBR.0000000000000017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

多囊卵巢综合征(Polycystic ovarian syndrome, PCOS)是一种常见的妇科内分泌综合征,以代谢异常和生殖功能障碍为特征,包括排卵异常、高雄激素和多囊卵巢表现。大多数多囊卵巢综合征患者超重或肥胖,特别是中心型。这加重了多囊卵巢综合征的临床表现,最终增加了不孕的风险。奥利司他是唯一获得美国食品和药物管理局批准的减肥药。奥利司他是一种长效的胃肠道脂肪酶抑制剂,可以有效地减少脂肪的吸收,增加脂肪的排泄,从而达到减肥的目的。在肥胖型PCOS患者中,奥利司他可以减轻体重,改善脂质代谢和胰岛素抵抗,改善性激素紊乱,对妊娠结局有积极影响。本文综述了奥利司他治疗对肥胖多囊卵巢综合征女性代谢和生育的影响。关键词:高雄激素;胰岛素抵抗;肥胖;奥利司他;多囊卵巢综合征;怀孕的结果
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of orlistat on obese women with polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is a common gynecological endocrine syndrome characterized by metabolic abnormality and reproductive dysfunction, including ovulation abnormality, hyperandrogenism and polycystic ovarian manifestations. Most PCOS patients are overweight or obese, particularly the central type. This aggravates the clinical manifestations of PCOS and ultimately increases the risk of infertility. Orlistat is the only weight loss drug approved by the US Food and Drug Administration. As a long-lasting gastrointestinal lipase inhibitor, orlistat can effectively reduce the absorption of lipid and increase lipid excretion, thereby achieving weight loss. In obese PCOS patients, orlistat can reduce weight, improve lipid metabolism and insulin resistance, improve sex hormone disorder, and have a positive effect on pregnancy outcome. This review summarizes the impact of orlistat treatment on metabolism and fertility in obese women with PCOS. Key words: hyperandrogenism; insulin resistance; obesity; orlistat; polycystic ovary syndrome; pregnancy outcome
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信